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I. Executive Summary 
 
Vancomycin is an antibiotic used regularly in hospitals across the world. The most 
concerning adverse effect of vancomycin is its documented effect on kidney function. This study 
examines the impact of two dosing strategies of vancomycin on patients’ kidney function at the 
University of Kentucky Albert B. Chandler Medical Center. It specifically focuses on patients on 
the orthopedic service because these patients traditionally receive higher doses of vancomycin 
for longer periods of time due to the severity of their infections, which puts them at an increased 
risk of vancomycin-induced nephrotoxicity compared to other patients.  
This study will serve as a precursor to a larger, hospital-wide study of vancomycin 
induced nephrotoxicity as the University of Kentucky Albert B. Chandler Medical Center 
recently changed its policy on dosing vancomycin from using the traditional trough-based dosing 
method to using area-under-the-curve (AUC) dosing in September 2017. This study compares 
patients on the orthopedic service who received longer durations of vancomycin therapy prior to 
the policy change with those receiving vancomycin after the policy change to determine the 
impact of the dosing strategies on patient outcomes, specifically acute kidney injury (AKI).  
 While this study is limited in patient population due to the recent nature of the policy 
change, the results support other studies that associate higher vancomycin troughs with increased 
risk for nephrotoxicity. Results also support studies that have found that patients often achieve a 
therapeutic AUC while maintaining lower troughs than expected. While this study did not show 
a significant difference between incidence of minor kidney injury between the two study 
populations, there was a significant difference in the incidence of more severe kidney injury 
(RIFLE Criteria Injury and Failure) in the two study populations, indicating that AUC-guided 
dosing is potentially safer for patients and results in fewer incidents of severe AKI. The follow-
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up study will be used to validate these results in other patient populations, including those with 
critical illness and different comorbidities.  
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III. Introduction to the Problem  
 
Vancomycin is an intravenous antibiotic used primarily in the hospital setting as either 
empiric treatment for infections caused by unknown organisms or targeted treatment for 
infections with resistant gram-positive bacteria such as methicillin-resistant Staphylococcus 
aureus (MRSA). This antibiotic is used very frequently due to its low cost and effectiveness, 
especially for MRSA infections (Huang 2018). However, one of the main adverse effects of 
vancomycin is its ability to cause an acute kidney injury (AKI), especially when used in 
combination with other antibiotics (Lexicomp 2019). Vancomycin-induced nephrotoxicity is 
generally seen in the elderly and those who receive vancomycin for a prolonged period of time 
(Lexicomp 2019).  
 Vancomycin blood levels must be monitored during the course of therapy because 
vancomycin is variable between patients (Lexicomp 2019). Traditionally, vancomycin has been 
monitored using trough levels, drawn an hour prior to the next dose (Osmond 2019). A trough 
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level is a measure of a drug in the blood at its lowest level, typically just prior to the next dose as 
this is the point in time when the blood level is the lowest due to clearance by the body over 
time. The goal for the trough levels is generally between 10mcg/mL and 20mcg/mL for 
vancomycin depending on the site and severity of infection (Lomaestro 2011). Data has shown 
that targeting higher trough levels is associated with higher incidence of acute kidney injury 
(Chavada 2017). However, targeting higher levels may be necessary for penetration of the 
antibiotic into the bone, brain, or other organs (Lomaestro 2011). Thus, the challenge is how to 
give patients enough vancomycin to clear their infection but not give such a high dose that 
results in kidney injury. This has been a consistent problem as vancomycin is the drug of choice 
for resistant Staphylococcus aureus infections and has been used for over sixty years (Levine 
2006). This is even more likely when vancomycin is given in combination with other 
nephrotoxic antibiotics, such as piperacillin/tazobactam (Navalkele 2016).  
 Due to widespread use of this antibiotic, much research has been done to determine the 
best target concentrations of vancomycin for different infections. A relatively new technique is 
using area-under-the-curve vancomycin exposure 
monitoring. This technique requires drawing two 
levels of vancomycin blood concentrations to 
determine a patient’s total exposure to vancomycin, 
not just their trough level (Neely 2014). By having 
two blood levels, one can calculate total 
vancomycin exposure through the area-under-the-
curve on a graph of blood concentration versus time 
(see Diagram 1). This technique requires more 
work by nursing and laboratory technicians to draw 
Diagram 1 
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blood and test it at the appropriate times; however, it is promising because it allows for a more 
individualized dosing regimen by providing more information to guide the selection of dose and 
frequency. Two levels allow one to mathematically determine vancomycin levels over time and 
give more precise information on exposure compared to single levels (Neely 2014). Additionally, 
having two levels allows one to calculate the true peak and trough, which is beneficial in the 
hospital setting as often these levels are not drawn on time. This has the potential to decrease 
incidence of kidney injury because it allows pharmacists and physicians to dose vancomycin 
more precisely to get the exposure of the antibiotic necessary to treat the infection (Neely 2014). 
This has been studied in some patient populations, but the policy of regularly using AUC dosing 
has not been implemented in many hospitals due to the increased workload on those involved in 
getting blood levels. This means that there are limited large trials involving AUC dosing as 
opposed to traditional trough monitoring. If further research proves that AUC dosing reduces 
adverse effects of vancomycin including kidney injury, it would encourage more hospitals to 
adopt this policy in the interest of patient safety.  
 The University of Kentucky Albert B. Chandler Medical Center changed its policy in 
September 2017 to solely dose vancomycin using the area-under-the-curve dosing scheme. Prior 
to this time period, vancomycin was dosed using target trough concentrations dependent on the 
site/severity of infection. This change allows for the perfect system for a retrospective study 
because it facilitates comparing safety of the area-under-the-curve dosing versus trough dosing at 
the same institution. The subjects in this study will include patients prior to the policy change 
and patients after the policy change to observe incidence of acute kidney injury and impact of 
this policy on patient safety. Results of this study could clarify the benefit of additional 
monitoring to conduct AUC calculations compared to trough monitoring. This study will focus 
on patients with bone and joint infections because these patients require long durations of 
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antibiotic therapy, most ranging from four to six weeks, which puts them at a higher risk of 
complications, including acute kidney injury (Lomaestro 2011). These patients also have similar 
disease states, including osteomyelitis, which requires a higher trough goal (15-20mcg/mL) to 
improve penetration of vancomycin into the bone. Evaluating the incidence of kidney injury in 
each clinical circumstance will allow for a recommendation for policies surrounding vancomycin 
use in this patient population. This research will test the new AUC policy for its effect on 
preventing acute kidney injuries and will increase the literature available to allow practitioners to 
make more informed decisions for their patients.  
 
IV. Literature Review 
 
Vancomycin History 
Vancomycin is a widely used antibiotic due to its excellent coverage of methicillin-
resistant Staphylococcus aureus (MRSA) (Levine 2006). While vancomycin was discovered in 
the 1950s, it was not used widely until the 1970s due to the emergence of resistant S. aureus 
(Levine 2006). While vancomycin covers S. aureus, numerous studies suggest that it is less 
effective than a beta-lactam antibiotic, except in the case of S. aureus that is resistant to beta-
lactam antibiotics (Schweizer 2011). Thus, the niche of vancomycin is in treating MRSA 
infections, rather than methicillin-susceptible Staphylococcus aureus (MSSA). The main adverse 
effect of vancomycin is acute kidney injury, estimated to occur in 12-43% of patients receiving 
vancomycin (Rybak 2009). While the exact mechanism of vancomycin-induced kidney injury is 
not fully understood, the primary theory is that vancomycin causes renal tubular ischemia and 
allergic interstitial nephritis, leading to a worsening of kidney function that is usually reversible 
(Vora 2016). The standard definition of vancomycin-induced nephrotoxicity is an increase in 
serum creatinine (SCr) of at least 0.5mg/dL or a 50% increase in serum creatinine from baseline 
(Martin 2010).  
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Osteomyelitis Recommendations 
 In this study, all of the patients have been admitted to the Bone and Joint team at the 
University of Kentucky Albert B. Chandler Medical Center. Most of these patients are being 
treated for suspected or confirmed osteomyelitis. The Infectious Disease Society of America 
(IDSA) released updated guidelines in 2015 about the treatment of osteomyelitis (Berbari 2015). 
IDSA guidelines are updated frequently and are the gold-standard for diagnosis, treatment, and 
monitoring of infective conditions. Osteomyelitis is an infection of the bone due to invasion of a 
microbial organism, most commonly Staphylococcus aureus (Berbari 2015). Risk factors for 
osteomyelitis include IV drug use, trauma, decubitus ulcers, orthopedic hardware, diabetes, 
peripheral vascular disease, peripheral neuropathy, and sickle cell disease (Berbari 2015). While 
most osteomyelitis is caused by bacterial organisms, there have been reports of fungal 
osteomyelitis (Berbari 2015). The diagnostic standard for osteomyelitis is an MRI to look for 
signs of bone remodeling and to distinguish osteomyelitis from trauma, neoplastic disease, or 
degenerative diseases (Berbari 2015).  
Treatment for osteomyelitis includes intravenous or highly potent oral antibiotics for 6 
weeks and possible surgical intervention depending on the extent of the infection (Berbari 2015). 
Patients with osteomyelitis have positive blood cultures less than 50% of the time, meaning that 
the majority of the time that osteomyelitis is confirmed with imaging, the offending organism is 
unidentified (Berbari 2015). As a result, many patients are on broad-spectrum antibiotics to 
cover a wide variety of organisms for the entire 4-6 week course because de-escalation to a 
single antibiotic is impossible without identification of the organism (Moenster 2013). Many 
patients are on vancomycin, for MRSA coverage, plus another agent, potentially piperacillin-
tazobactam or cefepime, which covers other gram-positive organisms as well as gram-negative 
organisms. IDSA guidelines recommend against the use of piperacillin-tazobactam given its 
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coverage of anaerobic organisms and the low likelihood of anaerobic organisms in osteomyelitis; 
however, piperacillin-tazobactam is widely used in hospitals due to its low cost and broad-
spectrum (Berbari 2015). General recommendations include use of vancomycin 15-20 mg/kg 
intravenously every 12 hours with adjustments made for body weight and renal function and an 
additional antibiotic such as cefepime (Berbari 2015). Additional IDSA guidelines recommend 
drawing trough levels, just prior to the next dose, to assess lowest blood concentration of 
vancomycin to aid in making decisions about the optimal dose for the patient (Tice 2004).  
Factors Influencing Kidney Injury in Patients Receiving Vancomycin 
Many reports have been published on factors influencing vancomycin-induced kidney 
injury, and there are multiple options proposed for combatting this issue. Larger vancomycin 
doses (exceeding 4 grams per day) have been associated with higher rates of nephrotoxicity 
(Lodise 2008). Additionally, higher vancomycin troughs (>15mg/L) are associated with 
increased odds of nephrotoxicity (van Hal 2013). A 2013 study reported an odds ratio of 2.67 for 
nephrotoxicity in patients with average vancomycin troughs of ≥ 15 mg/L compared to lower 
troughs of <15mg/L (van Hal 2013). However, the Infectious Diseases Society of America 
recommends targeting a trough of 15-20mg/L for osteomyelitis, given that it is a deep-seated 
infection and requires higher blood concentrations of antibiotic to fully penetrate the bone 
(Lomaestro 2011). This means that osteomyelitis patients are at increased risk of vancomycin-
induced nephrotoxicity because they regularly receive higher doses to target a higher serum 
trough level. Additionally, these patients are at higher risk due to the prolonged period of 
vancomycin therapy (Costa e Silva 2014). Greater than one week of vancomycin therapy is 
associated with an increase in incidence of nephrotoxicity from 6% to 21%, and two or greater 
weeks of vancomycin raises the risk to nearly 30% (Elvasi 2012). However, it is important to 
note that vancomycin-induced nephrotoxicity is generally reversible, and dialysis is required in 
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very few patients (van Hal 2013). In a meta-analysis of 15 studies, short-term dialysis was only 
needed in 3% of patients who developed kidney injury as a result of vancomycin (van Hal 2013).  
While vancomycin has an individual risk of causing nephrotoxicity, reports show that the 
risk of nephrotoxicity increases when vancomycin is used in combination with other antibiotics 
(Navalkele 2016). A 2016 retrospective study matched patients receiving vancomycin and 
piperacillin-tazobactam with patients receiving vancomycin-cefepime for at least 48 hours 
(Navalkele 2016). Of the 558 total patients, 29% of patients receiving vancomycin and 
piperacillin-tazobactam developed an acute kidney injury compared with 11% of patients on 
vancomycin and cefepime (Navalkele 2016). While this study was designed to determine which 
combination of medications was safer for those at risk of kidney injury, it also gave insight into 
the timing of acute kidney injury (Navalkele 2016). On average, patients who developed kidney 
injury on vancomycin and piperacillin-tazobactam had a 3-day onset compared to patients taking 
vancomycin and cefepime who had a 5-day onset of kidney injury (Navalkele 2016). In a 
comparison study between vancomycin monotherapy versus vancomycin and piperacillin-
tazobactam, 8.1% of patients developed acute kidney injury in the vancomycin group compared 
with 16.3% of patients in the combination therapy group (Burgess 2014).  
Vancomycin Monitoring 
A potential solution to the risk of acute kidney injury is changing the way most hospitals 
monitor vancomycin levels. Traditionally, a trough level is drawn 30 minutes prior to the next 
dose, which shows the lowest amount of vancomycin in the blood. Target concentrations for 
trough levels differ for different infections, but most experts recommend 10-15mg/L for less 
severe infections such as cellulitis and 15-20mg/L for deeper infections such as endocarditis or 
osteomyelitis (Lomaestro 2011). However, recent literature supports the use of drawing two 
blood levels and calculating the Area-Under-The-Curve (AUC) to determine total vancomycin 
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exposure. Calculating an AUC is a more precise way to quantify vancomycin exposure, and an 
AUC goal of 400-600 mg·h/liter in 24 hours is an accepted recommendation to maximize the 
effectiveness of vancomycin while keeping the risk of acute kidney injury low (Neely 2014). A 
2014 study looked at trough concentrations versus a two-level calculation of AUC and found that 
using trough concentrations underestimates the true Area-Under-The-Curve by about 25% 
(Neely 2014). Thus, by dosing patients based on current recommended trough goals, 
practitioners are likely achieving a higher AUC than needed to combat infection. This means that 
lower doses could potentially be used and still achieve clearance of the infection. In the same 
study, researchers estimated that 60% of adults with normal renal function and an AUC of ≥400 
mg·h/liter likely have a trough concentration below 15mg/L (Neely 2014). Since current 
guidelines recommend a trough goal of 15-20mg/L for osteomyelitis, it is very likely that using 
AUC monitoring instead of trough goals would result in the patient receiving less total 
vancomycin and being at a lower risk of developing acute kidney injury since high trough levels 
and high doses are risk factors for nephrotoxicity (Lomaestro 2011). A different study validated 
these results, finding that 26.7% of patients achieved a therapeutic AUC while trough levels were 
below recommended values (2017). Patients who developed acute kidney injury had an average 
trough level of 17.2mg/L compared to an average level of 13.1mg/L for patients who did not 
develop an acute kidney injury (Chavada 2017). This study also determined that patients with an 
AUC of >563 mg·h/liter were more likely to experience AKI than patients with a lower AKI 
(40% versus 11.2%) (Chavada 2017).  
Summary and Relevance to Current Study 
Results of this literature review show that osteomyelitis requires long duration of 
antibiotic therapy, with recommendations generally including vancomycin unless an organism 
has been identified (Berbari 2015). Additionally, vancomycin poses a significant threat as it is 
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associated with acute kidney injury, especially in combination with other antibiotics (Burgess 
2014). The risk of acute kidney injury is increased with high doses, high trough concentrations, 
and prolonged duration of therapy (Costa e Silva 2014). AUC monitoring as opposed to trough 
monitoring has been demonstrated to be effective, and likely allows for lower troughs and lower 
vancomycin doses while still maintaining appropriate total antibiotic exposure (Chavada 2017). 
No studies were found in the review that specifically looked at AUC versus trough monitoring in 
patients with osteomyelitis. Patients with osteomyelitis are at increased risk of developing 
nephrotoxicity because current guidelines recommend a high trough level (15-20mg/L) and 
extended duration of therapy (4-6 weeks) (Lomaestro 2011). This study will evaluate incidence 
of acute kidney injury through AUC versus trough monitoring for patients with osteomyelitis. 
Additional research should be done with AUC versus trough monitoring in these patients due to 
their increased risk and the potential for improved patient outcomes with a policy change.  
 
V. Research Design 
 
The purpose of this study is to evaluate the effectiveness of using Area-Under-The-Curve 
(AUC) monitoring for vancomycin as compared to traditional trough monitoring in decreasing 
the incidence of acute kidney injury (AKI). The University of Kentucky Albert B. Chandler 
Medical Center changed its policy from targeting vancomycin trough levels of 10-20mcg/mL to 
targeting an AUC of 400-600 in September 2017. All patients who received vancomycin prior to 
September 2017 were dosed based on trough levels as opposed to AUC. This study will compare 
acute kidney injury of those who received trough monitoring compared to those who received 
AUC monitoring. University of Kentucky vancomycin dosing guidelines prior to the policy 
change and after the policy change are attached (Appendices A & B).  
The University of Kentucky Center for Clinical and Translational Science (CCTS) 
reviewed patient charts in the Allscripts patient database and generated a list of patients who 
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were on the orthopedic service or had a consult order for the orthopedic service at UK Chandler 
Medical Center from October 2016 – December 2018 and received intravenous vancomycin for 
> 96 hours. This generated a total of 114 patients. Limiting the search to patients who received at 
least 4 days of vancomycin narrowed the list to patients who were on an extended duration of 
vancomycin and not short-course therapy to allow for the vancomycin blood concentration to 
approach steady-state and allow for accurate levels to be drawn. Six patients were excluded 
because no vancomycin levels were drawn. Four patients were moved from the AUC group to 
the trough group due to peak levels being drawn appropriately. One patient was duplicated, and 
the two entries were consolidated. After review, 103 patients were included in this study.  
I reviewed 49 patient charts in the trough group and 54 patient charts in the AUC group 
to record other parameters. Demographic parameters included age, gender, weight, and BMI. 
Clinical parameters included trough levels (for both groups), calculated AUCs (for AUC-guided 
dosing group), concurrent antibiotics, and blood cultures. Patients were classified as being on 
concurrent antibiotic therapy if they received an antibiotic (in addition to vancomycin) for > 48 
hours. Specific antibiotics were recorded as well as length of therapy. Kidney injury was defined 
using three criteria: Vancomycin 2009 Consensus Guidelines, AKIN Criteria, and RIFLE 
Criteria. To assess this, I recorded a baseline SCr upon admission to the hospital and the highest 
SCr during their hospital stay. Patients’ renal function was calculated using the Cockcroft-Gault 
equation. If the patient had a BMI greater than or equal to 30, the Salazar-Corcoran equation was 
used to calculate his/her creatinine clearance. Please see Appendix C for Cockcroft-Gault and 
Salazar-Corcoran equations and for a description of each nephrotoxicity criteria. 
 
VI. Results & Analysis 
 
103 patients were included in analysis, including 54 patients in the trough-guided dosing 
scheme and 49 patients in the AUC-guided dosing scheme. There were no statistically significant 
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differences in baseline characteristics. The majority of the patients were males, and the average 
age ranged from 48.2 in the AUC group to 51.1 in the trough group. On average, patients were 
classified as being overweight (BMI 25-29.9kg/m2) (Center for Disease Control and Prevention 
2017). The estimated creatinine clearance upon admission was above 100ml/min for both groups. 
A substantial percentage of patients were admitted from an outside hospital (37% of the trough 
group and 26.5% of the AUC group), which could indicate that their baseline serum creatinine is 
not a true baseline since they had the potential of receiving nephrotoxic agents at an outside 
hospital. The median number of days that patients received vancomycin was similar between 
both groups, 9 days for the trough group and 8 days for the AUC group.  
 
Table 1. Patient Demographics 
 Trough-Guided Dosing 
(n=54) 
AUC-Guided Dosing 
(n=49) 
P value 
Male Gender 31 (57.4%) 33 (67.3%) 0.30 
Age 51.1 48.2 0.26 
BMI 26.9 28.8 0.24 
Weight 78.5kg 85.9kg 0.12 
Admit Creatinine 0.82 0.80 0.74 
Admit Creatinine 
Clearance 
116 ml/min 123 ml/min 0.39 
Admit from OSH* 20 (37%) 13 (26.5%) 0.26 
Median Days 
Vancomycin 
9 8 0.79 
*Outside Hospital (a hospital not within University of Kentucky HealthCare) 
The majority of patients received concurrent antibiotics in addition to vancomycin. The 
most prevalent antibiotic was piperacillin/tazobactam, followed by metronidazole, cefepime, and 
cefazolin. The average days that a patient received piperacillin/tazobactam and cefepime was not 
statistically significantly different between the two groups.  
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Table 2. Antibiotic Profiles 
 Trough-Guided 
Dosing (n=54) 
AUC-Guided 
Dosing (n=49) 
P value 
Concurrent antibiotics  52 (96.3%) 48 (98%) 0.62 
Piperacillin/tazobactam 38 (70.4%) 33 (67.3%) 0.90 
Average days of 
piperacillin/tazobactam 
6.3 6.1 0.81 
Cefepime 12 (22.2%) 18 (36.7%) 0.11 
Average days of cefepime 8.9 11.1 0.49 
Metronidazole 9 (16.7%) 15 (30.6%) 0.10 
Cefazolin 7 (13%) 2 (4.1%) 0.11 
Meropenem 5 (9.3%) 1 (2%) 0.11 
Sulfamethoxazole/trimethoprim 2 (3.7%) 3 (6.1%) 0.58 
Ceftriaxone 3 (5.6%) 1 (2%) 0.35 
Ertapenem 1 (1.9%) 1 (2%) 0.95 
Amoxicillin/clavulanic acid  0 1 (2%) 0.32 
Ampicillin/sulbactam 0 1 (2%) 0.32 
Micafungin 3 (5.6%) 1 (2%) 0.35 
Aztreonam 1 (1.9%) 1 (2%) 0.95 
Levofloxacin 2 (3.7%) 0 0.16 
Ceftaroline 0 2 (4.1%) 0.16 
Rifampin 1 (1.9%) 1 (2%) 0.95 
Linezolid 0 1 (2%) 0.32 
Clarithromycin 0 1 (2%) 0.32 
Primaquine 0 1 (2%) 0.32 
Clindamycin 1 (1.9%) 0 0.32 
Doxycycline 1 (1.9%) 0 0.32 
Azithromycin 1 (1.9%) 1 (2%) 0.95 
Isoniazid 0 1 (2%) 0.32 
Rifabutin 0 1 (2%) 0.32 
Ethambutol 0 1 (2%) 0.32 
Oseltamivir 0 1 (2%) 0.32 
 
 The majority of patients had a positive culture, including tissue cultures, bone cultures, 
and/or blood cultures. Positive tissue cultures were the most prevalent type of culture. The 
majority of patients who had positive cultures grew methicillin-resistant staphylococcus aureus. 
Methicillin-susceptible staphylococcus aureus and other staphylococcal organisms were the next 
most prevalent organisms. There was no statistically significant difference between the 
organisms within the two groups, with the exception of SPACE organisms, including Serratia, 
Pseudomonas, Acinetobacter, Citrobacter, Enterobacter. These were significantly more 
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prevalent in the AUC-guided dosing scheme patient group. This is important to note in that these 
traditionally more resistant organisms to antibiotic therapy are more prevalent in the AUC group, 
which means that any impact found in the differences between efficacy of the two dosing 
schemes are not due to a decline in resistant organisms over time.  
 
Table 3. Culture Data 
 Trough-Guided Dosing 
(n=54) 
AUC-Guided Dosing 
(n=49) 
P value 
Positive Cultures 33 (61.1%) 33 (67.3%) 0.51 
Positive Tissue 
Cultures 
30 (55.6%) 29 (59.2%) 0.71 
Positive Blood 
Cultures 
4 (7.4%) 3 (6.1%) 0.80 
Positive Bone 
Cultures 
1 (1.9%) 4 (8.2%) 0.15 
MRSA 20 (37%) 19 (38.8%) 0.86 
MSSA 2 (3.7%) 5 (10.2%) 0.20 
Streptococcus spp.  3 (5.6%) 3 (6.1%) 0.66 
Staphylococcus spp.  2 (3.7%) 6 (12.2%) 0.12 
Enterococcus spp.  0 2 (4.1%) 0.16 
Corynebacterium 2 (3.7%) 0 0.16 
Proteus 1 (1.9%) 0 0.32 
Klebsiella 2 (3.7%) 0 0.16 
Escherichia coli 2 (3.7%) 1 (2%) 0.62 
SPACE Organisms 
(Serratia, 
Pseudomonas, 
Acinetobacter, 
Citrobacter, 
Enterobacter) 
2 (3.7%) 9 (18.4%) 0.03 
Anaerobic 
organisms 
2 (3.7%) 4 (8.2%) 0.35 
Fungal organisms 2 (3.7%) 0 0.16 
Atypical organisms 0 1 (2%) 0.32 
 
 
 For patients who had more than 1 trough value drawn and/or calculated, the median 
trough value was used to represent that patient’s vancomycin level. The average of those values 
was statistically significantly different between the two dosing groups. Patients who received 
trough-guided dosing had an average value of 17.8mcg/mL compared to an average value of 
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13mcg/mL for the AUC-guided dosing. This is important because 89.8% of patients receiving 
AUC-guided dosing achieved therapeutic AUC values. This means that it is likely that the trough 
goals are higher than necessary to achieve a therapeutic AUC. Additionally, the average of the 
median AUC for each patient was 505.5 which matches the goal AUC of 500 very closely, 
indicating that pharmacists were able to successfully target and achieve this goal.  
 There are no statistically significant differences in the Vancomycin 2009 Consensus 
Guidelines or AKIN Stage 1 or RIFLE Category Risk. However, there is slight significance 
(p<0.10) for definitions of more severe nephrotoxicity including AKIN Stage 2 and 3 and RIFLE 
Category Injury and Failure. RIFLE Category Injury achieves significance at the 1% level. No 
patients in the AUC-guided dosing group were classified as having AKIN stage 3 nephrotoxicity, 
RIFLE Category Injury, or RIFLE Category Failure compared to 5.6%, 11.1%, and 5.6% of 
patients in the trough-guided dosing scheme group for each category respectively.  
Table 4. Vancomycin Monitoring and Renal Impact 
 Trough-Guided Dosing 
(n=54) 
AUC-Guided Dosing 
(n=49) 
P value 
Average Median 
Trough Value 
17.8mcg/mL 13mcg/mL 0.0002 
Average Median AUC 
Value 
---- 505.5 ---- 
Patients with 
Therapeutic Troughs 
or AUCs 
43 (79.6%) 44 (89.8%) 0.15 
Average change in 
Creatinine Clearance 
23.3ml/min 16ml/min 0.16 
Median change in 
Creatinine Clearance 
15ml/min 6.6ml/min 0.28 
Vancomycin 2009 
Consensus Guidelines 
7 (13%) 2 (4.1%) 0.11 
AKIN Stage 1 11 (20.4%) 6 (12.2%) 0.27 
AKIN Stage 2 8 (14.8%) 2 (4.1%) 0.06 
AKIN Stage 3 3 (5.6%) 0 0.08 
RIFLE Category: Risk 12 (22.2%) 9 (18.4%) 0.63 
RIFLE Category: 
Injury 
6 (11.1%) 0 0.01 
RIFLE Category: 
Failure 
3 (5.6%) 0 0.08 
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A multivariate regression model was used to determine impact of variables on a patient’s 
change in creatinine clearance from baseline to their lowest point while on vancomycin. Age was 
a contributing factor as every year of age increases the estimated change in creatinine clearance 
by 0.501 ml/min (p<0.05). Additionally, each day of additional vancomycin therapy increased 
the estimated change in creatinine clearance by 1.164ml/min (p<0.05). Days of cefepime and 
ceftriaxone both had a negative relationship with change in creatinine clearance, likely because a 
higher number of days receiving cefepime and ceftriaxone means the patient is likely receiving 
fewer nephrotoxic medications. Additionally, a higher creatinine clearance on admission 
increased the estimated change in creatinine clearance (p<0.01). Finally, with every increase in 
the median trough of 1mcg/mL, this raised the estimated change in creatinine clearance by 
1.814ml/min. This supports current literature that higher trough levels are correlated with 
increased incidence of AKI. A higher median AUC was slightly significant (p<0.10) with a small 
decrease in estimated change in creatinine clearance. AUC-guided dosing was not a statistically 
significant variable on change in creatinine clearance. While the average change in creatinine 
clearance was higher in patients receiving trough-guided vancomycin dosing, it was not 
significantly higher. Thus, this data alone is insufficient to show that using AUC-guided dosing 
is definitively better than trough-guided dosing. 
Table 5. Regression Estimation Results for Change in Creatinine Clearance 
Variables Coefficient Robust Standard Error 
Age 0.501** 0.24 
Gender -1.208 6.55 
AUC-Guided Dosing 1.915 5.13 
Days of Vancomycin 1.164** 0.49 
Days of Piperacillin/Tazobactam 0.153 0.78 
Days of Cefepime -0.809* 0.48 
Days of Ceftriaxone -7.202** 3.24 
Admit Estimated Creatinine 
Clearance 
0.401*** 0.095 
Median Trough 1.814*** 0.35 
Median AUC -0.088* 0.05 
*** p<0.01, ** p<0.05, *p<0.1 
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A multivariable logistic regression was also performed for the 2009 Vancomycin 
Consensus Guidelines for nephrotoxicity. This evaluated the impact of various factors on 
whether a patient met the criteria for renal failure (increase in serum creatinine by ³0.5mg/dL 
and an increase of ³50% of baseline for 2 consecutive measurements) based on the 2009 
guidelines. The impact of AUC-guided dosing did not have a statistically significant impact on 
whether a patient met criteria for renal failure; however, age, days of vancomycin therapy, and 
median trough all met 10% significance indicating that higher age, higher median trough values, 
and longer durations of therapy with vancomycin are all associated with a higher risk of 
developing kidney injury that meets the 2009 Vancomycin Consensus Guidelines criteria for 
renal failure.  
Table 6. Multivariable Logistic Regression for 2009 Vancomycin Consensus Guidelines 
Variable Odds Ratio 95% Confidence Interval P value 
Age 1.067 0.990-1.150 0.091 
Gender 0.149 0.012-1.911 0.143 
AUC-Guided Dosing 1.268 0.087-18.390 0.862 
Admit Weight 0.889 0.768-1.029 0.115 
Days of Vancomycin 1.106 0.987-1.239 0.083 
Days of Piperacillin/Tazobactam 1.095 0.930-1.290 0.276 
Median Trough 1.344 0.982-1.839 0.064 
Admit Estimated Creatinine 
Clearance 
1.026 0.991-1.063 0.147 
 
 
A similar regression was created for the AKIN and RIFLE criteria, differentiating 
between each stage of renal failure as defined per the guidelines (Appendix C). Similar to the 
regression with the 2009 Vancomycin Consensus Guidelines, age, days of vancomycin therapy, 
and median trough were all statistically significant. However, in AKIN Stage 1 and AKIN Stage 
2, higher weight was a protective factor against kidney injury. Most significantly this data 
excludes AUC-guided dosing in analysis of AKIN Stage 3, RIFLE Criteria: Injury, and RIFLE 
Criteria: Failure because there were no incidences of any patients meeting these criteria while 
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receiving AUC-based dosing. This is highly indicative of a negative relationship between AUC-
guided dosing and incidence of nephrotoxicity. While these results cannot be used to say that 
these criteria of severe nephrotoxicity will never occur in patients receiving AUC-guided dosing 
of vancomycin, it is likely that AUC-guided dosing will decrease the incidence of severe 
nephrotoxicity in patients receiving vancomycin.   
 
Table 7. Multivariate Logistic Regression for AKIN Criteria 
 AKIN 1  AKIN 2  AKIN 3  
Variable Odds 
Ratio 
P Value Odds 
Ratio 
P Value Odds 
Ratio 
P Value 
Age 1.064 0.031 1.093 0.026 1.222 0.297 
Gender 0.725 0.705 0.186 0.172 *** *** 
AUC-Guided Dosing 0.942 0.941 0.776 0.849 *** *** 
Admit Weight 0.925 0.071 0.886 0.072 0.908 0.653 
Days of Vancomycin 1.010 0.030 1.102 0.098 1.176 0.403 
Days of Piperacillin/ 
Tazobactam 
0.985 0.830 1.060 0.472 0.923 0.802 
Median Trough 1.125 0.095 1.368 0.044 1.336 0.118 
Admit Estimated 
Creatinine Clearance 
1.022 0.031 1.039 0.023 1.018 0.782 
 
 
Table 8. Multivariate Logistic Regression for RIFLE Criteria  
 RIFLE 
Risk 
 RIFLE 
Injury 
 RIFLE 
Failure 
 
Variable Odds Ratio P Value Odds Ratio P Value Odds Ratio P Value 
Age 1.010 0.660 1.593 0.259 1.223 0.297 
Gender 1.413 0.644 0.00007 0.365 *** *** 
AUC-Guided 
Dosing 
1.078 0.916 *** *** *** *** 
Admit Weight 0.961 0.254 0.381 0.276 0.909 0.653 
Days of 
Vancomycin 
1.045 0.252 1.946 0.333 1.176 0.403 
Days of 
Piperacillin/ 
Tazobactam 
0.999 0.984 1.150 0.331 0.923 0.802 
Median 
Trough 
1.082 0.153 5.358 0.287 1.336 0.118 
Admit 
Estimated 
Creatinine 
Clearance 
  1.111 0.118 1.018 0.899 
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VII. Conclusion 
 
Support of Current Literature 
These results support current literature on risk factors for vancomycin-induced 
nephrotoxicity including age, duration of vancomycin therapy, and higher vancomycin serum 
trough values. Additionally, this study expands current understanding of the safety impacts of 
using an area-under-the-curve monitoring method for vancomycin as opposed to the traditional 
trough-monitoring strategy. In this study, patients who received trough-based dosing typically 
had higher trough values than those who received AUC-guided dosing. This supports the theory 
that current guidelines for target trough levels are overestimating the trough value needed to 
achieve a therapeutic AUC. This is likely a contributing factor to vancomycin-induced 
nephrotoxicity, as it is well-documented (and supported in this study) that higher doses and 
trough values are associated with an increased risk of kidney injury. 
Vancomycin-Induced Nephrotoxicity 
Using three different definitions of vancomycin-induced nephrotoxicity including the 
2009 Vancomycin Consensus Guidelines, the AKIN criteria, and the RIFLE criteria, this study 
evaluated the impact of various factors on kidney injury. There was a statistically significant 
difference between trough and AUC guided dosing approaches in the number of patients 
classified into these various stages of nephrotoxicity, with the most significant differences being 
in the criteria of more severe renal failure, including AKIN Stage 3, RIFLE Criteria: Injury, and 
RIFLE Criteria: Failure. There were no patients from the AUC-guided dosing cohort who met 
these criteria. This indicates that while AUC-guided dosing may not be the solution to preventing 
all incidences of vancomycin-induced nephrotoxicity, it could be used to prevent severe renal 
injury.  
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Weaknesses  
The primary weakness of this study is limited patient data. As a single-center 
retrospective study with a small sample size, the results of this study cannot be extrapolated to 
different patient populations. This study included patients on the orthopedic service who 
typically have higher targeted trough values due to the prevalence of deep-seated infections in 
these patients, specifically osteomyelitis. As a result, these patients receive higher doses of 
vancomycin to target a higher trough, which puts them at greater risk of developing acute kidney 
injury. This study cannot be applied to the general population of hospitalized patients because 
the doses and targeted troughs are likely lower than what was seen in this study. However, this 
study is critical in determining how to protect patients at highest risk for vancomycin-induced 
nephrotoxicity and should be taken into consideration when caring for them.  
Further Research 
More research will be required to evaluate the difference in AUC-guided dosing of 
vancomycin versus trough-guided dosing in critically ill patients as well as the average 
hospitalized patient. The University of Kentucky Albert B. Chandler Medical Center will 
evaluate AUC versus trough-guided dosing in a hospital-wide follow-up study to determine the 
impact for patients at a lower risk of acute kidney injury. Additional research should be done in 
other medical centers to evaluate the generalizability of these findings to different areas of the 
world.  
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VIII. Appendices 
 
Appendix A 
 
University of Kentucky Albert B. Chandler Medical Center Clinical Pharmacokinetics 
Guidelines- Updated January 2017 
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Appendix B 
 
University of Kentucky Albert B. Chandler Medical Center Clinical Pharmacokinetics 
Guidelines- Updated July 2017 
 
 
 
 25 
 
  
 26 
Appendix C 
 
Nephrotoxicity Categories 
 
 
(Finch 2017) 
 
 
 
Cockcroft-Gault Equation (1976) 
 
 
 
 
 
Salazar-Corcoran Equation for BMI³30m2 (1988) 
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